Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Teriparatide Contraindications in Hypoparathyroidism

Rationale for Contraindication

  • Teriparatide is a recombinant human parathyroid hormone analog that works as an anabolic agent to increase bone formation, and its FDA-approved indications are specifically for treatment of osteoporosis in patients with high fracture risk, not for hypoparathyroidism 1, 2
  • Teriparatide therapy can lead to hypercalcemia, which would be particularly dangerous in patients with hypoparathyroidism who are already being managed for calcium balance 3

Alternative Treatment Options for Osteoporosis in Hypoparathyroidism

  • Bisphosphonates (oral or IV) are the recommended first-line therapy for osteoporosis in patients with complex medical conditions, with options including Alendronate (70mg weekly oral), Risedronate (35mg weekly oral), and Zoledronic acid (5mg IV annually) 1, 2, 4
  • Denosumab (60mg subcutaneous every 6 months) may be considered as a second-line option, as it works through a different mechanism than teriparatide 3, 5
  • Raloxifene (60mg daily) may be considered in postmenopausal women without history of thromboembolic events 2

Management Considerations for Osteoporosis Treatment

  • Regular monitoring of serum calcium, phosphorus, and vitamin D levels is recommended 2
  • Bone mineral density testing via DEXA scan at baseline and follow-up is recommended 2
  • Assessment of fracture risk using FRAX or other validated tools is recommended 7
  • Ensure adequate calcium (1200mg daily) and vitamin D (800 IU daily) intake for patients over 70 years 2

Potential Risks and Guidelines

  • The American College of Physicians guidelines for osteoporosis treatment do not recommend teriparatide as first-line therapy, even in patients without hypoparathyroidism 3, 7
  • Teriparatide carries a black box warning for potential risk of osteosarcoma, which further limits its use in complex patients 6